MnSOD Val16Ala polymorphism associated with retinopathy risk in diabetes: a PRISMA-compliant Meta-analysis of case-control studies
Author:
Fund Project:

Supported by the Natural Science Foundation of Shaanxi Province (No.2015JM8415).

  • Article
  • | |
  • Metrics
  • |
  • Reference [28]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    AIM: To investigate the association of Manganese superoxide dismutase (MnSOD) Val16Ala polymorphism with diabetic retinopathy (DR). METHODS: PubMed, Embase, China National Knowledge Infrastructure, and Wanfang databases were searched. The pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the association. Subgroup, sensitivity, and cumulative analyses were performed. Publication bias was also analyzed. RESULTS: Eight studies were included in the pooled analysis. The MnSOD Val16Ala polymorphism was associated with the risk of DR under the dominant model (OR=0.66, 95%CI=0.48-0.91, P<0.0001), this result was demonstrated to be relatively stable in cumulative analysis. No significant publication bias was found. This polymorphism was also associated with the risk of DR in Caucasians under the dominant model (OR=0.64, 95%CI=0.42-0.97, P=0.04,) and in Asians under the recessive model (OR=0.31, 95%CI=0.11-0.88, P=0.03). CONCLUSION: These findings suggest that the MnSOD Val16Ala polymorphism is a risk factor for DR, and that more attention should be paid to carriers of these susceptibility genes.

    Reference
    1 See JL, Wong TY, Yeo KT. Trends in the pattern of blindness and major ocular diseases in Singapore and Asia. Ann Acad Med Singapore 1998;27(4):540-546.
    2 Kangas-Kontio T, Vavuli S, Kakko SJ, Penna J, Savolainen ER, Savolainen MJ, Liinamaa MJ. Polymorphism of the manganese superoxide dismutase gene but not of vascular endothelial growth factor gene is a risk factor for diabetic retinopathy. Br J Ophthalmol 2009;93(10):1401-1406.
    3 Uhlmann K, Kovacs P, Boettcher Y, Hammes HP, Paschke R. Genetics of diabetic retinopathy. Exp Clin Endocrinol Diabetes 2006;114(6):275-294.
    4 Naudi A, Jove M, Ayala V, Cassanye A, Serrano J, Gonzalo H, Boada J, Prat J, Portero-Otin M, Pamplona R. Cellular dysfunction in diabetes as maladaptive response to mitochondrial oxidative stress. Exp Diabetes Res 2012;2012:696215.
    5 Kowluru RA, Kern TS, Engerman RL. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant defense system. Free Radic Biol Med 1997;22(4):587-592.
    6 Kowluru RA. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 2003;52(3): 818-823.
    7 Guidot DM, McCord JM, Wright RM, Repine JE. Absence of electron transport (Rho 0 state) restores growth of a manganese-superoxide dismutase-deficient Saccharomyces cerevisiae in hyperoxia. Evidence for electron transport as a major source of superoxide generation in vivo. J Biol Chem 1993;268(35):26699-26703.
    8 Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997;46 Suppl 2:S38-S42.
    9 Vanita V. Association of RAGE (p.Gly82Ser) and MnSOD (p.Val16Ala) polymorphisms with diabetic retinopathy in T2DM patients from north India. Diabetes Res Clin Pract 2014;104(1):155-162.
    10 Kowluru RA, Atasi L, Ho YS. Role of mitochondrial superoxide dismutase in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2006;47(4):1594-1599.
    11 Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D, Degoul F. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 2005;15(5):311-319.
    12 Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
    13 Niu YM, Du XY, Cai HX, Zhang C, Yuan RX, Zeng XT, Luo J. Increased risks between Interleukin-10 gene polymorphisms and haplotype and head and neck cancer: a meta-analysis. Sci Rep 2015;5: 17149.
    14 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-188.
    15 He H, He G, Wang T, Cai J, Wang Y, Zheng X, Dong Y, Lu J. Methylenetetrahydrofolate reductase gene polymorphisms contribute to acute myeloid leukemia and chronic myeloid leukemia susceptibilities: evidence from meta-analyses. Cancer Epidemiol 2014;38(5):471-478.
    16 Ye LX, Yang MP, Qiu H, Guo KQ, Yan JS. Association of the polymorphism in manganese superoxide dismutase gene with diabetic retinopathy in Chinese type 2 diabetic patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2008;25(4):452-454.
    17 Houldsworth A, Hodgkinson A, Shaw S, Millward A, Demaine AG. Polymorphic differences in the SOD-2 gene may affect the pathogenesis of nephropathy in patients with diabetes and diabetic complications. Gene 2015;569(1):41-45.
    18 Hovnik T, Dolzan V, Bratina NU, Podkrajsek KT, Battelino T. Genetic polymorphisms in genes encoding antioxidant enzymes are associated with diabetic retinopathy in type 1 diabetes. Diabetes Care 2009;32(12):2258-2262.
    19 Lee SJ, Choi MG. Association of manganese superoxide dismutase gene polymorphism (V16A) with diabetic macular edema in Korean type 2 diabetic patients. Metabolism 2006;55(12):1681-1688.
    20 Petrovic MG, Cilensek I, Petrovic D. Manganese superoxide dismutase gene polymorphism (V16A) is associated with diabetic retinopathy in Slovene (Caucasians) type 2 diabetes patients. Dis Markers 2008;24(1):59-64.
    21 Jia YK. Study on the relationship between polymorphism of manganese superoide dismutase gene and diabetic microvascular complications in type 2 diabetes mellitus. Tianjin Medical University, 2004.
    22 Zhao Z, Liu LM, and Zheng TS. Correlation of gene polymorphism of manganese superoxide dismutase and type 2 diabetic retinopathy. Journal of Shanghai Jiaotong University (Medical Science) 2006;26(9):965-967.
    23 Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol 2016;44(4):260-277.
    24 Kumaramanickavel G, Sripriya S, Ramprasad VL, Upadyay NK, Paul PG, Sharma T. Z-2 aldose reductase allele and diabetic retinopathy in India. Ophthalmic Genet 2003;24(1):41-48.
    25 Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Garcia-Orad A. A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J 2013;13(6):498-506.
    26 Henzen C. Diabetic Retinopathy and Neuropathy: New in 2015. Praxis (Bern 1994) 2015;104(12):631-634.
    27 Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008;57(6):1446-1454.
    28 Mollsten A, Marklund SL, Wessman M, Svensson M, Forsblom C, Parkkonen M, Brismar K, Groop PH, Dahlquist G. A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. Diabetes 2007;56(1):265-269.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Lei Huang, Jun Lyu, Qiu-Ping Liu,/et al.MnSOD Val16Ala polymorphism associated with retinopathy risk in diabetes: a PRISMA-compliant Meta-analysis of case-control studies. Int J Ophthalmol, 2017,10(4):639-645

Copy
Share
Article Metrics
  • Abstract:1287
  • PDF: 685
  • HTML: 259
  • Cited by: 0
Publication History
  • Received:August 23,2016
  • Revised:October 26,2016
  • Online: April 14,2017